Group 1 - U.S. cannabis-related stocks rebounded after reports that President Trump is expected to sign an executive order on cannabis rescheduling, boosting market sentiment [1][2] - The executive order aims to address the long-delayed rescheduling of cannabis, which has not served Americans who could benefit from its medical use [1] - The White House plans to reclassify cannabis from a Schedule I controlled substance to a Schedule III substance, which includes drugs with recognized medical uses [1] Group 2 - If the rescheduling is implemented, cannabis companies are expected to benefit from tax reductions and face fewer restrictions on interstate product distribution, improving profitability and operating conditions [2] - Following Trump's confirmation to advance the cannabis rescheduling plan, cannabis stocks like MSOS experienced a quick recovery in market sentiment [2] - Notable multi-state operators in the U.S. cannabis market include Ascend Wellness, Curaleaf Holdings, Cresco Labs, Green Thumb Industries, Trulieve Cannabis, Ayr Wellness, Verano Holdings, and Jushi Holdings [3]
特朗普拟签署大麻重新分级行政令 美加大麻股反弹
Zhi Tong Cai Jing·2025-12-17 16:07